<DOC>
	<DOCNO>NCT02345382</DOCNO>
	<brief_summary>To determine safety , tolerability , pharmacokinetics , maximum tolerate dose , recommend Phase II dose BAY1143572 once-daily intermittent dose schedule subject advance acute leukemia</brief_summary>
	<brief_title>Phase I Dose Escalation BAY1143572 Subjects With Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>Male female subject age &gt; /=18 year Subjects histologically cytologically confirm acute leukemia refractory exhaust available therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 12 week Adequate liver renal function assess follow laboratory requirement conduct within 14 day first dose study drug : Total bilirubin &lt; /=1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; /=2.5 time ULN ( &lt; /=5 time ULN subject liver involvement cancer ) International normalize ratio ( INR ) &lt; /=1.5 time ULN Estimated glomerular filtration rate ( eGFR ) &gt; /=50 mL/min per 1.73 m2 accord Modification Diet Renal Disease Study Group ( MDRD ) formula Negative serum urine pregnancy test must obtain within 7 day first dose study drug woman childbearing potential . Negative result must available study drug administration Women men reproductive potential must agree use highly effective contraception sexually active . This apply period signing informed consent 30 day last administration study drug . Highly effective contraception include hormonal contraception implant combine oral contraceptive , certain intrauterine device , bilateral tubal ligation , hysterectomy , vasectomy partner . In addition , use condom subject partner require . Known hypersensitivity study drug excipients preparation agent give association study History cardiac disease include congestive heart failure New York Heart Association ( NYHA ) Class &gt; /=III , unstable angina ( anginal symptom rest ) newonset angina ( within last 6 month ) myocardial infarction within past 6 month cardiac arrhythmia require antiarrhythmic therapy except betablockers digoxin ; evidence uncontrolled coronary artery disease ( e.g . major regional wall motion abnormality baseline echocardiography leave ventricular ejection fraction ( LVEF ) &lt; 45 % ) Previous pulmonary embolism within 12 month study entry Uncontrolled hypertension define systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg , despite optimal medical management stable antihypertensive treatment 7 day first dose study drug Moderate severe hepatic impairment , i.e . ChildPugh class B C Known history human immunodeficiency virus ( HIV ) infection Chronic active hepatitis B C , require antiviral therapy Serious , uncontrolled infection require systemic antibiotic , antifungal antiviral therapy Uncontrolled meningeal leukemia Prior allogeneic hematopoietic stem cell transplant within &lt; /=4 month first dose study drug ( Subjects must complete immunosuppressive therapy enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced acute leukemia</keyword>
</DOC>